BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

The first day of its sec­ondary list­ing in Hong Kong has proven slight­ly dis­ap­point­ing for BeiGene.

The Bei­jing-based can­cer drug­mak­er closed its trad­ing de­but down 1% af­ter falling as much as 5% dur­ing the day. De­spite re­cruit­ing eight heavy­weight in­vestors to ce­ment its whop­ping $903 mil­lion IPO, BeiGene failed to stir up ex­cite­ment in the re­tail tranche, which made up 9% of the to­tal shares of­fered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER